PARP 抑制剂对剂诱导的心脏毒性的心脏保护作用
Jae Hyun Kim1,2, Ja-Young Han3, Jae-Hee Kwon3
1School of Pharmacy and Institute of New Drug Development, Jeonbuk National University, Jeonju, Republic of Korea.
Investigational new drugs
|February 17, 2025
概括
在接受化疗的卵巢癌患者中,Poly (ADP-ribose) 聚合酶 (PARP) 抑制剂没有显著的心脏保护作用. 需要进一步的研究来确认对心脏不良事件的潜在益处.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 基于的化疗是卵巢癌的标准治疗方法.
- 心脏毒性是接受化疗的患者的一个重大问题.
- 聚基酶 (PARP) 抑制剂是具有潜在心脏保护性能的新兴疗法.
研究的目的:
- 评估PARP抑制剂在接受基化疗的上皮卵巢癌患者的心脏保护作用.
- 评估PARP抑制剂使用与心脏不良事件之间的关联,包括心肌梗塞,心肌病和心力衰竭.
主要方法:
- 使用国家索赔数据库 (2007-2022) 的回顾性队列研究.
- 包括2017年以后用基化疗治疗的卵巢,初级腹膜或输卵管癌患者.
- 倾向性得分匹配和物流/Cox回归分析以估计心脏事件的几率和危险比率.
主要成果:
- 总共有7,253名患者被分析;233名 (3.2%) 使用PARP抑制剂.
- 没有观察到PARP抑制剂具有统计学意义的心脏保护作用 (aOR 0.753,95% CI 0.275-2.059;aHR 0.601,95% CI 0.228-1.584).
- 一个定向的趋势表明了潜在的好处,需要进一步调查.
结论:
- 在这组卵巢癌患者中,PARP抑制剂没有显示出统计学上显著的心脏保护作用.
- 这些发现表明需要进行更大规模的随访研究,以充分了解PARP抑制剂在减轻化疗引起的心脏毒性的作用.
- 进一步的研究是必不可少的,以确认潜在的益处,并优化治疗策略为妇科恶性瘤.
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
457
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
457
01:26Heart Failure Drugs: Inotropic Agents
500
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
500
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
371
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
371
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.2K
01:02Long-patch Base Excision Repair
7.0K
Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
7.0K